A clinical trial of Hepcidin for people with haemochromatosis is about to start at Westmead Hospital.  Hepcidin is a protein that regulates iron in the body. People who are on stable venesections with a ferritin of  >150 and saturation of >45% are eligible to participate.  During the trial participants continue with their normal venesections while having weekly subcutaneous injections of Hepcidin.

If you are interested and can make weekly visits to Westmead Hospital for 12 weeks please  contact the Clinical Trials Co-Ordinator, Jasmine Canete on 88905396, Kindness Bondezzi  on 88906674 or the Storr Liver Centre on  88907705 for more information.